Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease.
Ikonisys has developed and refined its CellOptics® platform, the foundation for Ikonisys' products and services, enabling the transformation of today's non-invasive cell-based diagnostics to tomorrow's rare cell detection. These products enable large and regional reference labs, hospitals, research institutions and practice groups to reduce the risk of human error, lower costs, and expand test volume capacity, even during an industry-wide shortage of trained technical personnel. Most exciting, through its integration of intelligent imaging, microscopy, biology and informatics, Ikonisys is laying the foundation for detecting a single cell and identifying its molecular signals, a long-term key to maximizing patient health and wellness.
Ikonisys is privately held and is headquartered in New Haven, Connecticut.